Literature DB >> 23576806

Microarray determination of Bcl-2 family protein inhibition sensitivity in breast cancer cells.

Sandra G Hudson1, Devin R Halleran, Barbara Nevaldine, Anna Shapiro, Robert E Hutchison, Peter J Hahn.   

Abstract

This study tests the hypothesis that reverse transcription polymerase chain reaction (RT-PCR) microarrays can be used to predict the relative sensitivity to induction of apoptosis in breast cancer cells exposed to inhibitors of antiapoptotic Bcl-2 family proteins. Four cell lines, MDA-MB-231 (MDA-231) and MDA-MB-468 (MDA-468), BT-20 and T47-D were screened for relative expression of Bcl-2 family members A1, Mcl-1, Bcl-2, Bcl-xL and Bcl-w mRNA by RT-PCR microarrays and Western analysis. The four cell lines were treated with 1 μmol/L obatoclax (GX15-070) and/or 2 Gy radiation (RT) and monitored for apoptosis after 48 h. Cell lines showing the highest total fold-increase of Bcl-2 family member mRNA, MDA-231 and MDA-468, also showed the highest levels of apoptosis induction (approximately 70% with obatoclax alone and 82% with obatoclax plus RT). Cell lines with little or no increase in Bcl-2 family mRNA (BT-20 and T47-D) showed less apoptosis (30% following treatment with obatoclax and 42% with obatoclax plus RT). RT-PCR arrays can predict the relative apoptosis response of breast cancer cells to the pan Bcl-2 inhibitor obatoclax alone or when combined with radiation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23576806     DOI: 10.1177/1535370212474582

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  2 in total

Review 1.  Strategies for optimizing the response of cancer and normal tissues to radiation.

Authors:  Everett J Moding; Michael B Kastan; David G Kirsch
Journal:  Nat Rev Drug Discov       Date:  2013-07       Impact factor: 84.694

2.  Potential utility of the pan-Bcl-2 inhibitor GX15-070 (obatoclax) in cancer immunotherapy.

Authors:  Peter S Kim; Jeffrey Schlom
Journal:  Oncoimmunology       Date:  2014-06-25       Impact factor: 8.110

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.